Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

231

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

231 results for “Clinical feature”

Learn how ShareScore rates datasets ↗
dryad28/100

Data from: Hyperandrogenism and insulin resistance-induced fetal loss: evidence for placental mitochondrial abnormalities and elevated ROS production in pregnant rats that mimic the clinical features of PCOS

Women with polycystic ovary syndrome (PCOS) commonly suffer from miscarriage, but the underlying mechanism of PCOS‐induced fetal loss during pregnancy remains obscure and specific therapies are lacking. We used pregnant rats treated with 5α‐dihydrotestosterone (DHT) and insulin to investigate the impact of hyperandrogenism and insulin resistance on fetal survival and to determine the molecular link between PCOS conditions and placental dysfunction during pregnancy. Our study shows that pregnant rats chronically treated with a combination of DHT and insulin exhibited endocrine aberrations such as hyperandrogenism and insulin resistance that are strikingly similar to those in pregnant PCOS patients. Of pathophysiological significance, DHT+insulin‐treated pregnant rats had greater fetal loss and subsequently decreased litter sizes compared to normal pregnant rats. This negative effect was accompanied by impaired trophoblast differentiation, increased glycogen accumulation, and decreased angiogenesis in the placenta. Mechanistically, we report that over‐production of reactive oxygen species (ROS) in the placenta, mitochondrial dysfunction, and disturbed SOD1 and Keap1/Nrf2 antioxidant responses constitute important contributors to fetal loss in DHT+insulin‐treated pregnant rats. Many of the molecular pathways leading to placental abnormalities and fetal loss in DHT+insulin treatment were also seen in pregnant rats treated with DHT alone, whereas pregnant rats treated with insulin alone often exerted distinct effects on placental gene expression compared to insulin treatment in combination with DHT. We also found that treatment with the antioxidant N‐acetylcysteine (NAC) improved fetal survival in DHT+insulin‐treated pregnant rats, an effect related to changes in Keap1/Nrf2 and NFκB signaling. However, NAC administration resulted in fetal loss in normal pregnant rats, most likely due to PCOS‐like endocrine abnormality induced by the treatment. Our results suggest that the deleterious effects of hyperandrogenism and insulin resistance on fetal survival are related to a constellation of mitochondrial‐ROS‐SOD1/Nrf2 changes in the placenta. Our findings also suggest that physiological levels of ROS are required for normal placental formation and fetal survival during pregnancy.

opencc-zeroJun 2019View details →
zenodo28/100

CLINICAL AND IMMUNOLOGICAL FEATURES IN PATIENTS WITH COMORBID ALLERGIC RHINITIS

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2023View details →
zenodo28/100

CLINICAL AND LABORATORY FEATURES OF CHRONIC VIRAL HEPATITIS B, EFFECTIVENESS OF ETIOTROPIC THERAPY

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2024View details →
zenodo28/100

Detailed Clinical Features of MPS-3A and 3B Series.

<p>Detailed Clinical Features of MPS-3A and 3B Series.</p>

opencc-by-4.0Jan 2022View details →
zenodo28/100

FEATURES OF THE CLINICAL AND EPIDEMIOLOGICAL COURSE OF MEASLES AT THE CURRENT STAGE

Open the record for dataset details and reuse information.

opencc-by-4.0Oct 2024View details →
dryad28/100

Clinical features in X-linked myotubular myopathy carriers

<p>Objective: To characterize the spectrum of clinical features in a cohort of X-linked myotubular myopathy (XL-MTM) carriers, including prevalence, genetic features, clinical symptoms and signs, as well as associated disease burden.</p> <p>Methods: We performed a cross-sectional online questionnaire study among XL-MTM carriers. Participants were recruited from patient associations, medical centers and registries in the United Kingdom, Germany and the Netherlands. We used a custom-made questionnaire, the Checklist Individual Strength (CIS), the Frenchay Activities Index (FAI), the SF-12 Health survey and the McGill Pain Questionnaire (MPQ). Carriers were classified as manifesting or non-manifesting, based on self-reported ambulation and muscle weakness.</p> <p>Results: The prevalence of manifesting carriers in this study population (n=76) was 51%, subdivided into mild (independent ambulation, 39%), moderate (assisted ambulation, 9%) and severe (wheelchair-dependent, 3%) phenotypes. In addition to muscle weakness, manifesting carriers frequently reported fatigue (70%) and exercise intolerance (49%). Manifesting carriers scored higher on the overall CIS (p = 0.001), the fatigue sub-scale (p &lt; 0.001) and least severe pain sub-scale (p = 0.005) than non-manifesting carriers. They scored lower on the FAI (p = 0.005) and the physical component of the SF-12 Health survey (p &lt; 0.001).</p> <p>Conclusions: The prevalence of manifesting XL-MTM carriers may be higher than currently assumed, most having a mild phenotype and a wide variety of symptoms. Manifesting carriers are particularly affected by fatigue, limitations of daily activities, pain and reduced quality of life. Our findings should increase awareness and provide useful information for health care providers and future clinical trials.</p>

opencc-zeroSep 2021View details →
zenodo28/100

Contrastive learning-based histopathological feature infers molecular subtypes and clinical outcomes of breast cancer from unannotated whole slide images

<p>The breast cancer cohort&nbsp;came from the Changzhou Second&nbsp;People&#39;s Hospital&nbsp;(CZSPH)&nbsp;in&nbsp;Jiangsu, China.&nbsp;This cohort&nbsp;collected 91 FFPE WSIs from 90 breast cancer&nbsp;patients, including 15&nbsp;recurrence cases within 5 years.</p>

opencc-by-4.0May 2023View details →
ClinicalTrials.gov28/100

Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms

ClinicalTrials.gov study NCT07397715. IPD Sharing: YES. Countries: 3. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Clinical Evaluation Of MP26 Features in Adults

ClinicalTrials.gov study NCT02927327. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features.

ClinicalTrials.gov study NCT06685458. IPD Sharing: NO. Countries: 0. Publications: 11.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Elastofibroma Dorsi: Clinical Features, Surgical Outcomes, and Risk Factors

ClinicalTrials.gov study NCT07010224. IPD Sharing: YES. Countries: 0. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Clinical Features and Linked MEchanisms in Acute Risk-free AMI

ClinicalTrials.gov study NCT06716177. IPD Sharing: UNDECIDED. Countries: 0. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Clinical, Structural and Mechanical Features in Patients With Left Bundle Branch Block.

ClinicalTrials.gov study NCT04328649. IPD Sharing: NO. Countries: 0. Publications: 12.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

The Clinical Features of Combined Central and Peripheral Demyelination

ClinicalTrials.gov study NCT04664647. IPD Sharing: Not stated. Countries: 0. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II

ClinicalTrials.gov study NCT02577887. IPD Sharing: NO. Countries: 4. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD

ClinicalTrials.gov study NCT03721588. IPD Sharing: NO. Countries: 0. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease

ClinicalTrials.gov study NCT00921128. IPD Sharing: Not stated. Countries: 0. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Correlation of Audiovisual Features With Clinical Variables and Neurocognitive Functions in Bipolar Disorder, Mania

ClinicalTrials.gov study NCT03857438. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

ClinicalTrials.gov study NCT04971590. IPD Sharing: NO. Countries: 4. Publications: 0.

closedIPD-NOFeb 2026View details →
dryad28/100

Clinical and pathological features of cognitive-predominant corticobasal degeneration

Open the record for dataset details and reuse information.

publicNov 2019View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record